Market Overview

UPDATE: Ascendiant Capital Markets Reiterates Buy Rating, Lowers PT on StemCells

Share:
Related STEM
Maxim Still Calling For 900% Upside At StemCells After Latest Phase II Data
Earnings Scheduled For March 23, 2016

In a report published Monday, Ascendiant Capital Markets reiterated its Buy rating on StemCells (NASDAQ: STEM), but slightly lowered its price target from $2.60 to $2.25.

Ascendiant Capital noted, “The Company ended the quarter with cash of $22 MM. Thus far in Q4, they have raised an additional $5.6 MM in cash from the exercise of warrants and sale of additional shares via their ATM facility. We are decreasing our Q4 2012 GAAP EPS, and 2013 GAAP EPS estimate, to reflect the higher number of shares outstanding. For Q4, our EPS estimate is lowered by $0.03 to ($0.15), and for 2013, our EPS estimate is decreased by $0.11 to ($0.58).”

StemCells closed on Friday at $1.76.

Latest Ratings for STEM

DateFirmActionFromTo
Apr 2016Rodman & RenshawAssumesBuy
Nov 2015H.C. Wainwright AnnAssumesBuy
May 2015Cantor FitzgeraldInitiates Coverage onBuy

View More Analyst Ratings for STEM
View the Latest Analyst Ratings

Posted-In: Ascendiant Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (STEM)

View Comments and Join the Discussion!